Nuvation Bio Inc. (NUVB) research

Nuvation Bio Inc.
ShareXLinkedInReddit
Sector
Pharmaceuticals
Last price
$5.85
As of

Nuvation Bio Inc. (NUVB): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.

As of . Source: SEC EDGAR filings for NUVB. Method and limitations.

SHARE THIS CARD

Share the NUVB intelligence card

A branded snapshot of NUVB: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion NUVB intelligence card preview
Post to X
LIVE TERMINAL

See NUVB live in the terminal

Track NUVB's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live NUVB terminal, free

Active signals for NUVB

FREE, NO ACCOUNT

Every signal on NUVB, as it fires

You are seeing 5 of 55 signals recorded on NUVB since 2026-06-02.

The five above landed across 2 days. The other 50 were recorded on 5 other days. 40 of the 55 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in NUVB (2026Q2)

Manager / securityMarket value% portfolioQoQ
D. E. Shaw & Co., Inc.CUSIP 67080NAA9 · 2026Q2$28.8M0.01%,
CITADEL ADVISORS LLCCUSIP 67080NAA9 · 2026Q2$16.7M0.00%,
CITADEL ADVISORS LLCCUSIP 67080N101 · 2026Q2$11.3M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 67080NAA9 · 2026Q2$8.6M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 67080N101 · 2026Q2$7.6M0.01%,
TWO SIGMA INVESTMENTS, LPCUSIP 67080N101 · 2026Q2$7.1M0.01%,
D. E. Shaw & Co., Inc.CUSIP 67080N101 · 2026Q2$6.5M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 67080N101 · 2026Q2$2.1M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, NUVB

NUVB against its peers

NUVB's operating margin of -338.7% ranks in the 18th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.

MetricNUVBPeer medianPercentilen
Revenue FY62.9M USD585M USD2620
Gross marginn/a53.3%n/a7
Operating margin-338.7%10.6%1818
Net margin-325.3%1.0%1819
Return on equity-66.9%-9.3%1621
P / En/a14.6xn/a10

Peers (25): TRVI, BHC, OCUL, NKTR, ANIP, SUPN, HRMY, GPCR, XERS, OMER, INVA, PAHC, ANRO, OGN, AMLX, TARS, ALMS, AMPH, PCRX, ESPR, ACRS, COLL, LQDA, AMRX, AVIR. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NUVB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more NUVB signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NUVBand get the insider, 13F, options, and confluence read in one view.

Open the live NUVB terminal, free